Annual Report 2024

Seeking Alpha / 46 minutes ago 2 Views

Lysaker, 30 April 2025

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

3 hours from now
Postal Realty Trust, Inc. Reports First Quarter 2025 Results

3 hours from now
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

3 hours from now
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations

3 hours from now
Rubicon Organics Announces Upsize of Private Placement Offering under the Listed Issuer Financing Exemption

3 hours from now